Alemtuzumab

Alemtuzumab Uses, Dosage, Side Effects, Food Interaction and all others data.

Humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein,CD52. The Campath-1H antibody is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Campath is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin.

Campath is used to treat leukemia by exploiting antibody mediated lysis of CD52 presenting cells. The CD52 antigen is a cell surface protein found on essentially all B and T lymphocytes, a majority of monocytes, macrophages and most granulocytes. The CD52 antigen is not present on erythrocytes or hematopoetic stem cells. In leukemia there is an excess of B and T cells, so Campath permits selective reduction of lymphocyte populations.

Trade Name Alemtuzumab
Availability Prescription only
Generic Alemtuzumab
Alemtuzumab Other Names Alemtuzumab
Related Drugs Gilenya, Tysabri, Venclexta, Vumerity, rituximab, Rituxan, cyclophosphamide, Copaxone, Imbruvica, Tecfidera
Weight 10mg/ml, 30mg/ml,
Type Intravenous Solution, Intravenous
Formula C6468H10066N1732O2005S40
Weight 145453.8 Da
Groups Approved, Investigational
Therapeutic Class
Manufacturer
Available Country United States
Last Updated: September 19, 2023 at 7:00 am
Alemtuzumab
Alemtuzumab

Uses

Alemtuzumab is a monoclonal anti-CD52 antibody used in the treatment of B-cell chronic lymphocytic leukemia and relapsing forms of multiple sclerosis.

Alemtuzumab (Campath) is a monoclonal antibody therapy used for treatment of B-cell chronic lymphocytic leukemia.

Alemtuzumab is also used to associated treatment for these conditions: Autoimmune Hemolytic Anemia, B-Cell Chronic Lymphocytic Leukemia, Graft Versus Host Disease (GVHD), Kidney Transplant Rejection, Relapsing Remitting Multiple Sclerosis (RRMS), T-Cell Prolymphocytic Leukemia, Conditioning regimens for allogeneic stem cell transplantation therapy

How Alemtuzumab works

Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells.

Food Interaction

No interactions found.

Volume of Distribution

  • 0.18 L/kg

Half Life

~288 hrs

Innovators Monograph

You find simplified version here Alemtuzumab

*** Taking medicines without doctor's advice can cause long-term problems.
Share